Balyasny Asset Management
NRIX icon

Balyasny Asset Management’s Nurix Therapeutics NRIX Stock Holding History

Balyasny Asset Management’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-118,481
Closed -$2.25M – 3318
2025
Q4 		$2.25M Sell
118,481
-3,102
-3% -$44.6K ﹤0.01% 1799
2025
Q3 		$1.12M Buy
+121,583
New +$1.26M ﹤0.01% 2067
2024
Q1 		– Sell
-22,581
Closed -$233K – 2953
2023
Q4 		$233K Sell
22,581
-3,694
-14% -$25.3K ﹤0.01% 2265
2023
Q3 		$207K Buy
+26,275
New +$240K ﹤0.01% 2026
2022
Q4 		– Sell
-15,930
Closed -$208K – 3078
2022
Q3 		$208K Buy
+15,930
New +$252K ﹤0.01% 2301
2021
Q3 		– Sell
-78,527
Closed -$2.08M – 2274
2021
Q2 		$2.08M Buy
78,527
+35,072
+81% +$1.03M 0.01% 994
2021
Q1 		$1.35M Buy
+43,455
New +$1.64M 0.01% 1162

Other funds holding NRIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Balyasny Asset Management's NRIX Position: Q1 2026 in Review

Balyasny Asset Management sold out of Nurix Therapeutics (NRIX) in Q1 2026, closing a stake of 118,481 shares — an estimated $2.25M sold.

Balyasny Asset Management first reported a position in NRIX in Q1 2021 and held it in 7 quarters. The position peaked at $2.25M in Q4 2025. 195 funds tracked by Wall St. Rank hold NRIX as of Q1 2026.

  • Balyasny Asset Management reported no remaining Nurix Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 118,481 Nurix Therapeutics shares in Q1 2026, an estimated $2.25M.
  • Balyasny Asset Management first reported a position in Nurix Therapeutics in Q1 2021 and held it in 7 quarters.
  • Balyasny Asset Management's Nurix Therapeutics position peaked at $2.25M in Q4 2025.
  • 195 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.